Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Stem-Cell Therapeutics for Spinal Injury Treatment

By HospiMedica International staff writers
Posted on 02 Oct 2008
New technologies may lead to stem cell-based therapies for victims of paralysis due to spinal cord injuries, helping them recover the use of their bodies without the risk of cell-transplant induced pain syndromes. More...


Researchers at the University of Colorado (Denver, USA), in collaboration with researchers at the University of Rochester (NY, USA) used signal molecules, known to be involved in the generation of embryonic astrocytes during spinal cord development, to make pure cultures of two different types of astrocytes from glial-restricted precursor (GRP) cells. The two astrocyte-derived cells, however, had remarkably different effects on the spinal repair process. GRP-derived astrocytes (GDAs) derived from GRPs treated with bone morphogenetic protein-4 (BMP-4), were able to promote robust axon regeneration and functional recovery when transplanted into rat spinal cord injuries. In contrast, transplantation of GDAs generated by exposure to the ciliary neurotrophic factor (CNTF), the other major signaling pathway involved in astrogenesis, resulted in failure of axon regeneration and functional recovery. Moreover, the transplantation of the GDACNTF cells promoted the onset of mechanical allodynia and thermal hyperalgesia at two weeks after injury, an effect that persisted through five weeks post-injury. Delayed onset of similar neuropathic pain was also caused by transplantation of undifferentiated GRPs. However, rats transplanted with GDAsBMP did not exhibit pain syndromes. The research teams considered the distinction between the effects of GDAsBMP, GDACNTF, and undifferentiated GRP cells a breakthrough that might change the way stem cell technologies are used to repair spinal cord injuries. The study was published in the September 19, 2008, edition of the Journal of Biology, an open access publication of BioMed Central (BMC).

"It has long been a concern that therapies that promote growth of nerve fibers in the injured spinal cord would also cause sprouting of pain circuits,” said lead author Stephen Davies, Ph.D., an associate professor of neurosurgery at the University of Colorado. "However, by using GDAsBMP to repair spinal cord injuries we can have all the gains without the pain, while these other cell types appear to provide the opposite – pain but no gain.”

Controlling the development of stem cells immediately before transplanting them into injured spinal cords is essential, since doctors cannot rely on the injured tissues of the body to create the right types of cells from naïve stem cells. The GRP cell, which is central to this effort, and the techniques for turning them into astrocytes were discovered by Doctors Margot Mayer-Proschel, Mark Noble, and Christoph Proschel of the department of biomedical genetics at the University of Rochester.

Related Links:
University of Colorado
University of Rochester


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.